With nearly 3% of American men over 40 taking some form of testosterone, the financial and public health stakes couldn't be higher. But in increasing numbers, physicians are saying that research on the safety of testosterone patches, creams and emollients is anything but conclusive, leaving doctors and patients alike uncertain about how and whether to treat a condition newly branded as "low T."
In the wake of studies linking testosterone to increased heart attack and stroke risk, a physician writing in Lancet Endocrinology weighed in on the testosterone debate urging caution and more - and better - research.
"What, then, can older patients be told about the risks associated with testosterone?" asked University of Washington endocrinologist Dr. Stephanie T. Page in the Lancet on Monday. "Physicians need to admit they simply do not know and use conservative treatment guidelines to guide therapeutic decisions."
The new calls come against the backdrop of testosterone's meteoric rise in the United States, spurred by an aggressive "disease awareness" campaign to alert men to the diffuse symptoms of "low T" (weight gain, low energy, flagging sex drive) and by relentless marketing of prescription testosterone products. Between 2000 and 2011, prescriptions for testosterone supplementation have grown fivefold in the United States, netting the makers of the products $1.6 billion annually.
If you or a loved one have suffered a heart attack, stroke, pulmonary embolism or blood clot while taking AndroGel or another testosterone medication, please call our experienced AndroGel attorneys at (888) 606-5297 for a free consultation about your potential AndroGel lawsuit.